A novel MAPK-microRNA signature is predictive of hormone-therapy resistance and poor outcome in ER-positive breast cancer

Clinical Cancer Research

Volumn 21, Issue 2, 2015, Pages 373-385

  Miller, Philip C ^a   Clarke, Jennifer ^a,b,c   Koru Sengul, Tulay ^a,b   Brinkman, Joeli ^a   El Ashry, Dorraya ^a,b  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR; MICRORNA; TAMOXIFEN; TRANSCRIPTOME;

ARTICLE; BASAL BREAST CANCER; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL FEATURE; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DISEASE SPECIFIC SURVIVAL; ENZYME ACTIVATION; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; EVENT FREE SURVIVAL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC ANALYSIS; HER2 NEGATIVE BREAST CANCER; HUMAN; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; MOLECULAR DYNAMICS; PREDICTIVE VALUE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; BREAST NEOPLASMS; DRUG RESISTANCE; ENZYMOLOGY; FEMALE; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MICRORNAS; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; TAMOXIFEN; TRANSCRIPTOME; TREATMENT OUTCOME;

EID: 84920988706     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2053     Document Type: Article

References (53)

1. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, et al. Validation and clinical utility of a 70-gene prognostic signature for women with nodenegative breast cancer. J Natl Cancer Inst 2006;98:1183-92.
2. Paik S, Shak S, Tang G, Kim C, Baker J, CroninM, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.
3. Knight WA, Livingston RB,Gregory EJ,Mcguire WL. Estrogen-receptor as an independent prognostic factor for early recurrence in breast-cancer. Cancer Res 1977;37:4669-71.
4. Desombre ER, Thorpe SM, Rose C, Blough RR, Andersen KW, Rasmussen BB, et al. Prognostic usefulness of estrogen-receptor immunocytochemical assays for human-breast cancer. Cancer Res 1986;46:4256-64.
5. Clark GM, Mcguire WL. Steroid-receptors and other prognostic factors in primary breast-cancer. Semin Oncol 1988;15:20-5.
6. Toi M, Osaki A, Yamada H, Toge T. Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. Eur J Cancer 1991; 27:977-80.
7. Sainsbury JR, Farndon JR, NeedhamGK, Malcolm AJ, Harris AL. Epidermalgrowth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1987;1:1398-402.
8. Rimawi MF, Shetty PB, Weiss HL, Schiff R, Osborne CK, Chamness GC, et al. Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer 2010;116: 1234-42.
9. Loi S, Haibe-Kains B,Majjaj S, Lallemand F, Durbecq V, Larsimont D, et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A 2010;107:10208-13.
10. Lopez-Knowles E, O'Toole SA, McNeil CM, Millar EK, Qiu MR, Crea P, et al. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 2010;126:1121-31.
11. Hernandez-Aya LF, Gonzalez-Angulo AM. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist 2011;16: 404-14.
12. Bayliss J, Hilger A, Vishnu P, Diehl K, El-Ashry D. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response. Clin Cancer Res 2007;13:7029-36.
13. Holloway JN, Murthy S, El-Ashry D. A cytoplasmic substrate of mitogenactivated protein kinase is responsible for estrogen receptor-alpha downregulation in breast cancer cells: the role of nuclear factor-kappaB. Mol Endocrinol 2004;18:1396-410.
14. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El-Ashry D. Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol Endocrinol 2001;15:1344-59.
15. Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D. Activation of mitogen-activated protein kinase in estrogen receptor alphapositive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res 2006;66:3903-11.
16. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A 2004;101:11755-60.
17. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8.
18. Jay C, Nemunaitis J, Chen P, Fulgham P, Tong AW. miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol 2007;26:293-300.
19. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005;65:7065-70.
20. Lowery AJ,Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, et al. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res 2009;11:R27.
21. Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 2006;5:24.
22. Enerly E, Steinfeld I, Kleivi K, Leivonen SK, Aure MR, Russnes HG, et al. miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS ONE 2011;6:e16915.
23. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 2007;8:R214.
24. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Kerin MJ. MicroRNAs as novel biomarkers for breast cancer. J Oncol 2009;2009:950201.
25. Janssen EA, Slewa A, Gudlaugsson E, Jonsdottir K, Skaland I, Soiland H, et al. Biologic profiling of lymph node negative breast cancers by means of microRNA expression. Mod Pathol 2010;23:1567-76.
26. Burroughs AM, Ando Y, de Hoon MJ, Tomaru Y, Suzuki H, Hayashizaki Y, et al. Deep-sequencing of human Argonaute-associated small RNAs provides insight into miRNA sorting and reveals Argonaute association with RNA fragments of diverse origin. RNA Biol 2011;8:158-77.
27. Cochrane DR, Cittelly DM, Howe EN, Spoelstra NS,McKinsey EL, LaPara K, et al. MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer. Horm Cancer 2010;1:306-19.
28. Di Leva G, Gasparini P, Piovan C, Ngankeu A, Garofalo M, Taccioli C, et al. MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst 2010;102:706-21.
29. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 2008;283:29897-903.
30. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007;131:1109-23.
31. Buffa FM, Camps C, Winchester L, Snell CE, Gee HE, Sheldon H, et al. microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res 2011;71:5635-45.
32. NIH" NCIa. The Cancer Genome Atlas. 2011 [cited 2011]. Available from: http://cancergenome. nih.gov/.
33. Lyng MB, Laenkholm AV, Sokilde R, Gravgaard KH, Litman T, Ditzel HJ. Global MicroRNA expression profiling of high-risk ER breast cancers from patients receiving adjuvant tamoxifen mono-therapy: a DBCG study. PLoS ONE 2012;7:e36170.
34. Curtis C, Shah SP, Chin SF, TurashviliG, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012;486:346-52.
35. Dvinge H, Git A, Graf S, Salmon-Divon M, Curtis C, Sottoriva A, et al. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature 2013;497:378-82.
36. Niemela M, Kauko O, Sihto H,Mpindi JP, Nicorici D, Pernila P, et al. CIP2A signature reveals theMYCdependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes. Oncogene 2012;31: 4266-78.
37. Zhong L, Zhu K, Jin N, Wu D, Zhang J, Guo B, et al. A systematic analysis of miRNA-mRNA paired variations reveals widespread miRNA misregulation in breast cancer. BioMed Res Int 2014;2014:291280.
38. Hua L, Li L, Zhou P. Identifying breast cancer subtype related miRNAs from two constructed miRNAs interaction networks in silico method. BioMed Res Int 2013;2013:798912.
39. Bleckmann A, Leha A, Artmann S, Menck K, Salinas-Riester G, Binder C, et al. Integrated miRNA and mRNA profiling of tumor-educated macrophages identifies prognostic subgroups in estrogen receptor-positive breast cancer. Mol Oncol 2014;pii:S1574-7891(14)00178-1.
40. Dweep H, Sticht C, Pandey P, Gretz N. miRWalk-database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. J Biomed Inform 2011;44:839-47.
41. Good PI. Resampling methods: a practical guide to data analysis. 3rd ed. Boston, MA: Birkhauser; 2006.
42. Westfall PH, Young S. Resampling-based multiple testing: examples and methods for p-value adjustment. New York: Wiley; 1993.
43. Team RDC. R: a language and environment for statistical computing, R Foundation for Statistical Computing. 2. 12. 2 ed; 2011.
44. Chou J, Lin JH, Brenot A, Kim JW, Provot S, Werb Z. GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nat Cell Biol 2013;15:201-13.
45. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120:635-47.
46. Kumarswamy R, Mudduluru G, Ceppi P, Muppala S, Kozlowski M, Niklinski J, et al. MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. Int J Cancer 2012;130:2044-53.
47. Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 2009;8:1055-66.
48. Yu Z, Wang C, Wang M, Li Z, Casimiro MC, Liu M, et al. A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol 2008;182:509-17.
49. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 2008;283:31079-86.
50. Foekens JA, Sieuwerts AM, Smid M, Look MP, de Weerd V, Boersma AW, et al. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci U S A 2008;105:13021-6.
51. Rodriguez-Gonzalez FG, Sieuwerts AM, Smid M, Look MP, Meijer-van Gelder ME, de Weerd V, et al. MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat 2011;127: 43-51.
52. Ward A, Balwierz A, Zhang JD, Kublbeck M, Pawitan Y,Hielscher T, et al. Reexpression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene 2013;32: 1173-82.
53. McGlynn LM, Kirkegaard T, Edwards J, Tovey S, Cameron D, Twelves C, et al. Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients. Clin Cancer Res 2009;15:1487-95.